Jubilant Pharmova Reports Strong Financial Growth and Improved Liquidity in June 2025 Results

Jubilant Pharmova, a midcap player in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending June 2025. The company reported a profit before tax (PBT) of Rs 142.40 crore, reflecting a year-on-year growth of 58.57%. This positive trend in PBT indicates a strong operational performance for the quarter.
Additionally, the profit after tax (PAT) for the latest six months stands at Rs 258.92 crore, showcasing a year-on-year increase of 22.90%. This growth in PAT further underscores the company's solid financial health in the near term.

Jubilant Pharmova has also made notable strides in its financial structure, with a debt-equity ratio recorded at 0.44 times, marking a consistent reduction in borrowing relative to equity capital over the last five half-year periods. Furthermore, the company achieved its highest inventory turnover ratio at 6.37 times, indicating improved efficiency in selling inventory.

Lastly, the cash and cash equivalents have reached Rs 1,088.80 crore, the highest in the last six half-year periods, suggesting an enhancement in short-term liquidity.

In light of these developments, the stock has undergone an adjustment in evaluation, reflecting the recent financial performance.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.